Humana 3Q 2026: Revenue $41.16B, EPS $1.33 — 10-Q Summary

Humana reported 3Q 2026 revenue of $41.16B, up 26.1% YoY, driven by Medicare membership growth and higher premiums. Net income fell 16.9% to $162M, with EPS at $1.33. Insurance membership grew 20.3%, but the segment saw a $303M operating loss. CenterWell revenue rose 40.4% to $1.9B, though costs increased.

Original reporting
Published Nov 6, 2026, 7:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 7:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Humana 3Q 2026: Revenue $41.16B, EPS $1.33 — 10-Q Summary — source image
Decision brief

The 30-second read

$HUMBullishHigh
01

Why it matters

Earnings miss may trigger short‑term sell‑off, but strong membership growth offers upside potential.

02

Market read

First earnings report for a large-cap insurer; material numbers likely move the stock.

03

What to watch

CenterWell's 40% revenue jump and new Medicare GLP‑1 bridge could improve future profitability.

Relevance 8/10Novelty 9/10Timing: post-market release

Background

Humana's Q3 2026 10‑Q filing provides the first public disclosure of its quarterly results.

Company-level read

Ticker impact

$HUMBullishHigh confidence
Context

Humana reported Q3 2026 revenue of $41.16B and EPS of $1.33, a 17.9% decline YoY.

Expected impact

downward pressure as the market prices in the earnings shortfall

Evidence & confidence

Revenue grew 26% but net income fell 16.9% and EPS dropped 17.9%, indicating margin compression.

Market effects

Highlights pressure on health insurers from rising benefit ratios and Medicare cost risks.

U.S. health insurance sector may see modest pullback following the miss.

Limited to U.S. insurers; no broader macro impact.

Counterpoint

Revenue growth outpaces earnings decline; investors may focus on top-line momentum.

Key entities

  • Humana Inc.

    U.S. health insurance provider.

Related articles

$HUMMedAI 8/10

Humana Inc. Q3 2026 Earnings Call Summary

Humana Inc. raised its 2026 adjusted EPS outlook due to strong operational performance and medical cost trends. The company is focusing on top quartile Star ratings and expects 2027 membership growth. A joint venture with BlackRock aims to improve balance sheet efficiency. Humana anticipates a 3%+ individual MA margin by 2028, with 2027 showing progress. The divestment of Gentiva is expected to close in Q4 2026, providing $900 million in pretax proceeds.

$HUMHighAI 8/10

Humana (HUM) Q3 2026 Earnings Call Transcript

Humana (HUM) reported Q3 2026 earnings with adjusted EPS of $17.17 YTD and a Q3 loss of $0.70, down from $3.24 YoY. Full-year adjusted EPS guidance raised to at least $9.50. GAAP EPS for Q3 was $1.33, down from $1.62 in 2025. The company expects $900M in pretax proceeds from Gentiva divestment. Medicare Advantage enrollment and Star ratings improved, but Part D cost trends are expected to rise to 14-15% in 2027.

$HUMHighAI 8/10

Humana Raises Profit Floor on Lower Costs

Humana (HUM) raised its 2026 adjusted earnings guidance to at least $9.50 per share from $9.00, citing lower costs. Q3 insurance benefit ratio was 93.7%, better than expected. Shares fell 0.59% in pre-market trading. Humana's Medicare Advantage membership grew 23% this year.

$HUMHighAI 8/10

HUM Q3 FY2026 earnings call

Humana Inc. reported Q3 2026 earnings exceeding expectations, raising full-year adjusted EPS guidance to at least $9.50. The company cited favorable medical cost trends and strong execution. Management highlighted progress in clinical quality, Medicaid expansion, and capital allocation, including a divestiture and a new joint venture. Humana expects 2027 Medicare Advantage membership growth and an 8%-9% medical cost trend, with risks and opportunities outlined.